NMTC vs. INFU, MGRM, ICAD, NSPR, MBOT, FONR, SRTS, MLSS, CTSO, and GUTS
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include InfuSystem (INFU), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), Microbot Medical (MBOT), FONAR (FONR), Sensus Healthcare (SRTS), Milestone Scientific (MLSS), Cytosorbents (CTSO), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs.
NeuroOne Medical Technologies (NASDAQ:NMTC) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
NeuroOne Medical Technologies received 54 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 71.59% of users gave NeuroOne Medical Technologies an outperform vote.
InfuSystem has a net margin of 1.12% compared to NeuroOne Medical Technologies' net margin of -82.17%. InfuSystem's return on equity of 2.78% beat NeuroOne Medical Technologies' return on equity.
In the previous week, NeuroOne Medical Technologies had 3 more articles in the media than InfuSystem. MarketBeat recorded 4 mentions for NeuroOne Medical Technologies and 1 mentions for InfuSystem. NeuroOne Medical Technologies' average media sentiment score of 0.53 beat InfuSystem's score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.
NeuroOne Medical Technologies has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 10.2% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
InfuSystem has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
InfuSystem has a consensus target price of $13.00, indicating a potential upside of 175.48%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than NeuroOne Medical Technologies.
Summary
InfuSystem beats NeuroOne Medical Technologies on 14 of the 18 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy NMTC Stock Free NMTC Stock Alerts